Log in to Thinknum

Interested in Thinknum?

Request a demo

LinkedIn Profile

Access Adaptimmune Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Records

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Ticker Sector Ticker Industry
nasdaq:adap 9045855 May 21st, 2019 12:00AM Adaptimmune 9.5K 367.00 Open Biotechnology May 20th, 2019 10:05PM May 20th, 2019 10:05PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 20th, 2019 12:00AM Adaptimmune 9.5K 365.00 Open Biotechnology May 19th, 2019 10:05PM May 19th, 2019 10:05PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 19th, 2019 12:00AM Adaptimmune 9.5K 365.00 Open Biotechnology May 19th, 2019 03:27PM May 19th, 2019 03:27PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 18th, 2019 12:00AM Adaptimmune 9.5K 365.00 Open Biotechnology May 18th, 2019 10:28AM May 18th, 2019 10:28AM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 17th, 2019 12:00AM Adaptimmune 9.5K 365.00 Open Biotechnology May 17th, 2019 04:01PM May 17th, 2019 04:01PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 16th, 2019 12:00AM Adaptimmune 9.4K 366.00 Open Biotechnology May 15th, 2019 10:05PM May 15th, 2019 10:05PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 15th, 2019 12:00AM Adaptimmune 9.4K 365.00 Open Biotechnology May 15th, 2019 08:32AM May 15th, 2019 08:32AM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 14th, 2019 12:00AM Adaptimmune 9.4K 367.00 Open Biotechnology May 14th, 2019 09:04AM May 14th, 2019 09:04AM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 13th, 2019 12:00AM Adaptimmune 9.4K 367.00 Open Biotechnology May 12th, 2019 10:05PM May 12th, 2019 10:05PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology
nasdaq:adap 9045855 May 12th, 2019 12:00AM Adaptimmune 9.4K 367.00 Open Biotechnology May 12th, 2019 01:36PM May 12th, 2019 01:36PM Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Open Open 60 Jubilee Avenue, Milton Park Abingdon Oxfordshire GB OX14 4RX Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.